Phibro Animal Health (NASDAQ:PAHC) closed out fiscal 2026 with numbers that speak for themselves. Full-year net sales topped $1.5 billion, adjusted EBITDA climbed 39% to $255 million, and adjusted diluted earnings per share jumped 48% to $3.22. The results, covering the quarter and year ended June 30, mark the first complete fiscal year since the company folded in a large medicated feed additive portfolio, and management used its earnings call on August 27 to argue the deal is finally paying off on its own ...